120 related articles for article (PubMed ID: 29710706)
1. Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units.
Lage C; Suarez AG; Pozueta A; Riancho J; Kazimierczak M; Bravo M; Jimenez Bonilla J; de Arcocha Torres M; Quirce R; Banzo I; Vazquez-Higuera JL; Rabinovici GD; Rodriguez-Rodriguez E; Sánchez-Juan P
J Alzheimers Dis; 2018; 63(3):1025-1033. PubMed ID: 29710706
[TBL] [Abstract][Full Text] [Related]
2. Practical utility of amyloid and FDG-PET in an academic dementia center.
Sánchez-Juan P; Ghosh PM; Hagen J; Gesierich B; Henry M; Grinberg LT; O'Neil JP; Janabi M; Huang EJ; Trojanowski JQ; Vinters HV; Gorno-Tempini M; Seeley WW; Boxer AL; Rosen HJ; Kramer JH; Miller BL; Jagust WJ; Rabinovici GD
Neurology; 2014 Jan; 82(3):230-8. PubMed ID: 24353340
[TBL] [Abstract][Full Text] [Related]
3. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
4. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
[TBL] [Abstract][Full Text] [Related]
5. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
Banzo I; Jiménez-Bonilla J; Ortega-Nava F; Quirce R; Martínez-Rodríguez I; de Arcocha-Torres M; Rodríguez E; Vázquez JL; Sánchez PJ; Martínez-Amador N; Ibañez-Bravo S; Carril JM
Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
[TBL] [Abstract][Full Text] [Related]
6. Impact of molecular imaging on the diagnostic process in a memory clinic.
Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
[TBL] [Abstract][Full Text] [Related]
7. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
Shea YF; Ha J; Lee SC; Chu LW
Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
[TBL] [Abstract][Full Text] [Related]
8. The value of FDG combined with PiB PET in the diagnosis of patients with cognitive impairment in a memory clinic.
Liu F; Shi Y; Wu Q; Chen H; Wang Y; Cai L; Zhang N
CNS Neurosci Ther; 2024 Feb; 30(2):e14418. PubMed ID: 37602885
[TBL] [Abstract][Full Text] [Related]
9. Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [
Hellwig S; Frings L; Bormann T; Vach W; Buchert R; Meyer PT
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):312-323. PubMed ID: 30094462
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
11. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome.
Parmera JB; Coutinho AM; Aranha MR; Studart-Neto A; de Godoi Carneiro C; de Almeida IJ; Fontoura Solla DJ; Ono CR; Barbosa ER; Nitrini R; Buchpiguel CA; Brucki SMD
Mov Disord; 2021 Mar; 36(3):651-661. PubMed ID: 33206389
[TBL] [Abstract][Full Text] [Related]
13. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
14. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
[TBL] [Abstract][Full Text] [Related]
15. Management impact of FDG-PET in dementia: results from a tertiary center memory clinic.
Elias A; Woodward M; Rowe CC
J Alzheimers Dis; 2014; 42(3):885-92. PubMed ID: 24961944
[TBL] [Abstract][Full Text] [Related]
16. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.
de Wilde A; van der Flier WM; Pelkmans W; Bouwman F; Verwer J; Groot C; van Buchem MM; Zwan M; Ossenkoppele R; Yaqub M; Kunneman M; Smets EMA; Barkhof F; Lammertsma AA; Stephens A; van Lier E; Biessels GJ; van Berckel BN; Scheltens P
JAMA Neurol; 2018 Sep; 75(9):1062-1070. PubMed ID: 29889941
[TBL] [Abstract][Full Text] [Related]
17. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
18. The correlation between striatal and cortical binding ratio of
Sauerbeck J; Ishii K; Hosokawa C; Kaida H; Scheiwein FT; Hanaoka K; Rominger A; Brendel M; Bartenstein P; Murakami T
Ann Nucl Med; 2018 Jul; 32(6):398-403. PubMed ID: 29730823
[TBL] [Abstract][Full Text] [Related]
19. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.
Rabinovici GD; Rosen HJ; Alkalay A; Kornak J; Furst AJ; Agarwal N; Mormino EC; O'Neil JP; Janabi M; Karydas A; Growdon ME; Jang JY; Huang EJ; Dearmond SJ; Trojanowski JQ; Grinberg LT; Gorno-Tempini ML; Seeley WW; Miller BL; Jagust WJ
Neurology; 2011 Dec; 77(23):2034-42. PubMed ID: 22131541
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study.
Segovia F; Gómez-Río M; Sánchez-Vañó R; Górriz JM; Ramírez J; Triviño-Ibáñez E; Carnero-Pardo C; Martínez-Lozano MD; Sopena-Novales P
J Alzheimers Dis; 2018; 65(3):765-779. PubMed ID: 30103321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
